Literature DB >> 15211072

Autoimmune responses to amyloid structures of Abeta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease.

M A Gruden1, T B Davudova, M Malisauskas, V V Zamotin, R D E Sewell, N I Voskresenskaya, I A Kostanyan, V V Sherstnev, L A Morozova-Roche.   

Abstract

We have found an increased level of serum antibodies to the prefibrillar structures of both Abeta(25-35) peptide and human lysozyme in Alzheimer's disease (AD) patients compared to age-matched controls, indicating that autoimmunity is implicated in AD. In the serum of AD patients with a long-term duration (>15 years) the titer of serum antibodies to aggregates of Abeta(25-35) peptide increased by approximately 5-fold, whilst the antibody titer to lysozyme protofilaments decreased by approximately 8-fold compared to patients with AD duration of <5 years. The content of immunoglobulins of the A, G and M types declined, particularly in AD duration of >15 years. An increase in the concentration of immune complexes and higher lysozyme activity was detected in the serum of all patients and this was suggestive of an inflammatory reaction. We propose that the autoimmune response to different amyloid structures in AD can be viewed as a clearance pathway targeting amyloid development. Autoimmune response can be exploited as a marker of ongoing protein aggregation and hence be used as a diagnostic feature of AD. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15211072     DOI: 10.1159/000079197

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  13 in total

Review 1.  T-cells in Alzheimer's disease.

Authors:  Terrence Town; Jun Tan; Richard A Flavell; Mike Mullan
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 2.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

Review 3.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

4.  α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients.

Authors:  Kiran Yanamandra; Marina A Gruden; Vida Casaite; Rolandas Meskys; Lars Forsgren; Ludmilla A Morozova-Roche
Journal:  PLoS One       Date:  2011-04-25       Impact factor: 3.240

5.  ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects.

Authors:  Andrea C Klaver; Mary P Coffey; Lynnae M Smith; David A Bennett; John M Finke; Loan Dang; David A Loeffler
Journal:  J Neuroinflammation       Date:  2011-08-09       Impact factor: 8.322

6.  Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.

Authors:  Sofia Söllvander; Frida Ekholm-Pettersson; Rose-Marie Brundin; Gabriel Westman; Lena Kilander; Staffan Paulie; Lars Lannfelt; Dag Sehlin
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

7.  Autoimmune Responses to Soluble Aggregates of Amyloidogenic Proteins Involved in Neurodegenerative Diseases: Overlapping Aggregation Prone and Autoimmunogenic regions.

Authors:  Sandeep Kumar; A Mary Thangakani; R Nagarajan; Satish K Singh; D Velmurugan; M Michael Gromiha
Journal:  Sci Rep       Date:  2016-02-29       Impact factor: 4.379

8.  Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease.

Authors:  Andrea Marcello; Oliver Wirths; Thomas Schneider-Axmann; Malin Degerman-Gunnarsson; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-05-05       Impact factor: 3.575

9.  Kihi-to, a herbal traditional medicine, improves Abeta(25-35)-induced memory impairment and losses of neurites and synapses.

Authors:  Chihiro Tohda; Rie Naito; Eri Joyashiki
Journal:  BMC Complement Altern Med       Date:  2008-08-16       Impact factor: 3.659

10.  Amyloid Beta peptides differentially affect hippocampal theta rhythms in vitro.

Authors:  Armando I Gutiérrez-Lerma; Benito Ordaz; Fernando Peña-Ortega
Journal:  Int J Pept       Date:  2013-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.